Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The relative effectiveness of nine bone-seeking radionuclides with their progeny for the production of malignant skeletal tumors (mostly osteogenic sarcoma), principally by chronic alpha-particle irradiation, is examined with available data obtained from lifetime studies at three laboratories of pure-bred beagles exposed to graded dosages in controlled experiments. The lifetime tumor dose-rate/time-response relationships observed in beagles injected with 226Ra at the University of California at Davis, in which 123 cases of bone cancer (98% osteosarcoma) have been observed for dose rates between 0.05 and 20 rad/day, provide the basis for comparing the induction of bone cancer by the other radionuclides. All nine radionuclide studies were found to demonstrate with high precision (sigma g less than 1.2) a three-dimensional lognormal response relationship represented in two dimensions by the equation of the time to death from bone cancer t = KD-s, where t is the elapsed time to death, D is the average skeletal dose rate, K is a parameter characteristic of the radionuclide, risk level and exposure details, and S observed to be 0.29 (0.01 SE) and suggested to be exactly one-third for all the nine radionuclides. The results show the relative biological effectiveness (RBE) for bone-cancer induction potency with respect to radiation exposure from 226Ra to be 3.0 for 228Ra , 6.4 for 241Am, 6.6 for 249Cf , 252Cf and 253Es , 9.0 for 239Pu, 10.7 for 228Th , and 15.5 for 238Pu. The observed RBE values are interpreted in terms of the relative exposure of sensitive cells of the skeleton since they all involve primarily alpha irradiation. Scaling to people is accomplished using a response ratio (RR) of 3.6 with respect to beagles.
 ...
PMID:Comparison of the carcinogenicity of radium and bone-seeking actinides. 632 74

Bone tumours are comparatively uncommon, constituting only 0.5% of the total world cancer incidence. As Bone tumors consist of several distinct clinico-pathological entities, descriptive epidemiology of tumors at this site can be based only on studies where they can be distinguished. Ewing's sarcoma Chondrosarcoma and Osteosarcoma are the principal tumors involving bones. The basic data utilized for this study was collected from the Bombay Cancer Registry which was established in 1963, and is the first population based registry to be established in India. For studying the descriptive epidemiological variables the most recent 5 year incidence rates have been used. As a group, bone cancers represent 0.9% of the total number of incident cancer are seen in Greater Bombay. Males in general are seen to have a higher incidence of bone cancers than females. Ewing's sarcoma was found to be the commonest bone cancer in Bombay. The age specific incidence curves present striking differences according to cell types of bone cancer. Time trends in the incidence of these cancers, over the past 30 years have been presented. Our data indicate that there is a decreasing trend in incidence of bone cancers in females, whilst the rates are stable in males. Ionising radiation is the only environmental agent to cause this cancer. The discovery of other risk factors is the key prevention and will depend upon the experimental work undertaken to develop sub-clinical measures of risk that can be applied in interdisciplinary studies to identify more completely the causes of bone cancers.
 ...
PMID:Descriptive epidemiology of bone cancer in greater Bombay. 1022 99

Permanent human osteosarcoma cell lines are important tools for the study of bone cancer. As representative of an osteoblastic phenotype, they partly reflect their normal osteoblastic counterparts and, thus, may represent appropriate models to investigate the mechanisms involved in bone remodelling and in haematopoietic differentiation. In the present work, we describe a new human cell line, CAL 72, obtained from an osteosarcoma of the knee of a 10-year-old boy. These cells grow in continuous culture, and karyotypic analysis has revealed clonal abnormalities in number and structure, especially loss of chromosome Y. These cells exhibit morphological, immuno-histochemical and molecular characteristics of the osteoblastic lineage. Using RT-PCR, we have shown that the CAL 72 cell line expresses high levels of mRNA coding for several cytokines, such as G-CSF, GM-CSF, IL-1beta and IL-6. In view of this expression profile, the CAL 72 phenotype appears to be closer to normal primary osteoblasts than other reported osteosarcomas. Moreover, these cells express mRNA for both HGF and its receptor c-MET, suggesting that this autocrine loop might contribute to the invasiveness of the tumour from which CAL 72 originated.
 ...
PMID:Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). 1038 64

Low-grade intraosseous osteosarcoma is an uncommon form of bone cancer. It is occasionally difficult to recognize as a malignant tumor and is commonly misdiagnosed as a benign fibrous lesion. We retrospectively studied the records of 8 patients with low-grade intraosseous osteosarcoma in the files of the Tohoku Musculoskeletal Tumor Society in Japan. All tumors arose in the lower limb. The most common symptom was pain, with a duration exceeding 2 years in 4 patients. Radiologic findings, including those at magnetic resonance imaging (MRI), suggested malignancy in 5 lesions, whereas 3 were diagnosed as benign. Two patients initially presented with pathological fracture. The initial pathological diagnosis was malignant in 5 patients and benign in 3. All eight tumors were grade 1 in Broders' classification. The tumor showed a permeative pattern in all eight cases, but this pattern could not be confirmed in the multiple tiny fragments obtained as biopsy specimens in 3 cases. The number of silver-staining nucleolar organizer regions (AgNOR) per nucleus and MIB-1-positive rate were significantly higher in low-grade intraosseous osteosarcoma than in fibrous dysplasia, offering an advantage in differential diagnosis. Three patients (38%) developed high-grade sarcoma at the site of local recurrence after multiple intralesional excisions, and one of them died of the disease. The other 5 patients had a good clinical course after surgery with a wide margin. These findings indicate that preoperative diagnosis with radiologic investigation, including magnetic resonance (MR) imaging and histologic examination of biopsy specimens is essential in preparation for surgery with a wide margin, assuring a good clinical course, and the results of AgNOR and immunohistochemical MIB-1 staining might be helpful in differentiating low-grade intraosseous osteosarcoma from fibrous dysplasia.
 ...
PMID:Low-grade intraosseous osteosarcoma in northern Japan: advantage of AgNOR and MIB-1 staining in differential diagnosis. 1087 54

Nucleolar organizer regions [NORS] are loops of DNA that transcribe to ribosomal RNA. They can be visualized as intranuclear black dots by histochemical staining with a colloid silver solution. Silver stained nucleolar proteins (AgNORs) were counted in a variety of jaw bone tumours. In osteosarcomas, the number of AgNORs was also quantified before and after chemotherapy. Malignant bone tumour cells possessed more than five small AgNORs (5.54 +/- 0.44). Nuclei of benign jaw bone tumour cells had less than three (2. 97 +/-0.61). A significant difference in the number of AgNORs between osteosarcoma before chemotherapy (5.76 +/- 0.50) and after chemotherapy (3.89 +/- 1.65) was observed. (P < 0.05). The number ofAgNORs in recurrent osteosarcoma, recurrent ameloblastic carcinoma and recurrent chondrosarcoma was much higher than in their respective primary lesion but without statistical significant difference. The results of the present study indicate that the AGNOR count might help in determining malignancy, evaluating the effect of chemotherapy, and deciding the prognosis.
 ...
PMID:Evaluation of nucleolar organizer regions in tumours of the jaw bones. 1148 76

We used the nation-wide Swedish Family-Cancer Database to analyze the risk for bone cancer in offspring by parental cancers and in siblings of bone cancer probands. Additionally, the risk of second cancer following childhood bone cancer was investigated. In offspring, 1,190 bone cancers were diagnosed between years 1958 and 1996. Groups of offspring were compared by calculating standardized incidence ratios (SIRs) for bone cancer. Most bone cancer cases occurred sporadically. Parental breast (SIR 1.7) and prostate (SIR 1.7) cancers were associated with early-onset (<25 years) osteosarcoma in offspring, probably due to Li-Fraumeni syndrome. Giant cell sarcoma was increased by parental breast cancer (SIR 2.9), and early-onset chondrosarcoma by parental kidney cancers (SIR 6.8). Bone cancers conveyed a high risk of second bone and connective tissue cancer.
 ...
PMID:Parental cancer as a risk factor for bone cancer: a nation-wide study from Sweden. 1180 47

Fischer 344 rats (60/sex/group) were given daily subcutaneous injections of recombinant human parathyroid hormone (PTH)(1-34) for 2 years at doses of 0, 5, 30, or 75 microg/kg. Treatment caused substantial increases in bone mass consistent with the known pharmacologic effects of once-daily administration. As determined by quantitative computed tomography (QCT) and histomorphometry, bone mass was markedly increased. Substantial new bone formation resulted in a large decrease in marrow space accompanied by altered bone architecture. Bone proliferative lesions were observed in all PTH( 1-34)-treated groups. Osteosarcoma occurred in 3, 21, and 31 male rats and in 4, 12, and 23 female rats in the 5-, 30-, and 75-microg/kg treatment groups, respectively. Focal osteoblast hyperplasia, osteoma, and osteoblastoma were much less frequent. Although the specific cellular or molecular mechanisms responsible for the rat bone tumors have not been fully elucidated, the data suggest that these lesions resulted from the long duration of treatment and the exaggerated pharmacologic response of the rat skeleton to daily treatment with PTH(1-34). Important differences between the rat study and clinical use in adult humans suggest that the increased incidence of bone neoplasia in rats treated for 2 years is likely not predictive of an increased risk of bone cancer in skeletally mature adult humans being given PTH(1-34) for a limited period of time in the treatment of osteoporosis.
 ...
PMID:Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. 1205 48

A two-mutation carcinogenesis model has been applied to model osteosarcoma incidence in two data sets of beagles injected with 226Ra. Taking age-specific retention into account, the following results have been obtained: (1) a consistent and well-fitting solution for all age and dose groups, (2) mutation rates that are linearly dependent on dose rate, with an exponential decrease for the second mutation at high dose rates, (3) a linear-quadratic dose-effect relationship, which indicates that care should be taken when extrapolating linearly, (4) highest cumulative incidences for injection at young adult age, and highest risks for injection doses of a few kBq kg(-1) at these ages, and (5) when scaled appropriately, the beagle model compares fairly well with a description for radium dial painters, suggesting that a consistent model description of bone cancer induction in beagles and humans may be possible.
 ...
PMID:A consistent two-mutation model of bone cancer for two data sets of radium-injected beagles. 1240 Sep 50

The recent development of rodent models of bone cancer pain has started to provide the basis for demonstrating the particular neurochemical and behavioral entity of cancer pain. Behaviourally, both spontaneous pain and hyperalgesia related to mechanical, but not thermal, noxious stimuli have been described in cancer-bearing animals. We have carried out a histological and behavioural study focused on the reactivity to noxious heat in C3H/HeJ mice receiving an intratibial injection of 10(5) NCTC 2472 cells. These cells, able to induce an osteosarcoma, break through bone into soft tissues 2 weeks after cell inoculation, producing a macroscopical increase of the limb size from the fourth week. Thermal reactivity is diminished during the first 2 weeks after cell implantation, this hypoalgesia being reversed by the administration of naloxone (10 mg/kg). In contrast, during the fourth and fifth weeks after NCTC 2472 cell implantation, an increased nociceptive heat reactivity, instead of hypoalgesia, was obtained. This thermal hyperalgesia was prevented by the systemic administration of morphine (15 mg/kg). Throughout the whole period studied, mice showed signs of spontaneous pain behaviour that reached its maximum 3 weeks after inoculation. In conclusion, we show that the presence of thermal heat hyperalgesia is preceded by an initial opioid-mediated hypoalgesic state, in this murine model of bone cancer pain.
 ...
PMID:Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain. 1267 70

A five-year study was undertaken to determine the incidence of primary bone cancer in Canada in order to assess the effects of subsequent increases in background radiation, should such occur. Eight hundred and twenty-seven cases were investigated, and the annual incidence rate was estimated to be 6.3 per million population. Osteosarcoma was the most common type of tumour, accounting for more than half of all confirmed cases. Over 60% of the tumours occurred in males.
 ...
PMID:A MORTALITY STUDY OF PRIMARY TUMOURS OF BONE IN CANADA. 1426 Nov 50


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>